Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bumetanide nasal spray - Corstasis Therapeutics

Drug Profile

Bumetanide nasal spray - Corstasis Therapeutics

Alternative Names: RSQ-777-02

Latest Information Update: 24 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corstasis Therapeutics
  • Class Antihypertensives; Antiparkinsonians; Behavioural disorder therapies; Benzoic acids; Heart failure therapies; Sulfonamides; Vascular disorder therapies
  • Mechanism of Action Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Oedema

Most Recent Events

  • 03 Feb 2025 FDA assigns PDUFA action date of (14/09/2025) for bumetanide nasal spray for Oedema
  • 27 Jan 2025 Preregistration for Oedema in USA (Intranasal)
  • 25 Nov 2024 Clinical trials in Oedema (Intranasal) prior to November 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top